Traders News Issues Research, Growing Companies with New Product Development Catalysts
24 Abril 2018 - 7:05AM
InvestorsHub NewsWire
New York, NY -- April 24, 2018 -- InvestorsHub NewsWire
-- Max Sound Corporation (OTCBB:
MAXD), “MAX-D is a Proprietary Audio Process that
restores lost compressed harmonics & brings high definition
sound to digital media. MAXD is currently in negotiations with one
of the world’s leading Gaming Companies to distribute their line-up
of award winning games with MAXD HD Audio. MAXD is poised to be at
the forefront of servicing the digital coin industry by using its
successful HD Audio App while partnering and/or developing other
Apps in lifestyle, talent discovery, mindfulness and other social
experiences as a means to “airdrop” issuer’s coins in free
promotional giveaways to consumers.
Get our research reports and our low float feature report with no
obligation READ MORE
Copy and paste to browser may be required – https://secure.blueoctane.net/forms/KBZ53HQCKA06
Progressive Care, Inc. (OTCQB:
RXMD) through its subsidiaries Smart Medical Alliance,
Inc. and PharmCo, LLC, is a South Florida health services
organization. On April 13, 2018 PharmCo, LLC announced increased
prescriptions filled and revenue for March 2018. PharmCo, LLC
filled over 22,800 prescriptions during the month of March,
generating nearly $1.9 million in net revenues. Prescriptions
filled, and revenues increased by 20% and 18% respectively compared
to the same month last year.
Advaxis, Inc. (NASDAQ:
ADXS), a clinical and late stage biotechnology
company, focuses on the discovery, development, and
commercialization of Listeria monocytogenes (Lm) technology-based
immunotherapies. Their Lm Technology, A Proprietary Antigen
Delivery Platform that Activates the Immune System, naturally
represents an advancement in the field of immunotherapy, as its
comprehensive immune stimulation and priming redirects a
“pathogen-like” response against cancers.
Get our research reports with no obligation and our low float
feature report READ MORE
Copy and paste to browser may be required – https://secure.blueoctane.net/forms/KBZ53HQCKA06
Rising India, Inc., (OTCPK:
RSII), operating as Rising Biosciences, Inc.is a
research and development company focusing on oral and topical
cannabis and non-cannabis-based pharmaceuticals. Rising Biosciences
will also be rolling out its RBS0238 CLINICAL PEPTIDE SERUM (scar
serum) in Q2. The company expects their product line will be on
sale, available for national distribution, in late April/early May.
The serum produces visible results with an effective ingredient
base and delivery system.
Disclosure
Traders News Source LLC (TNS)
produces regular sponsored and non-sponsored reports, articles,
stock market blogs, and popular investment newsletters covering
small and micro-cap equity markets. TNS has two distinct and
independent departments. One department produces non-sponsored
analyst certified content generally in the form of press releases,
articles and reports covering equities listed on NYSE, NASDAQ and
OTC exchanges. The other produces sponsored content (in most cases
not reviewed by a registered analyst), which typically consists of
compensated investment newsletters, articles and reports covering
listed stocks and micro-caps. Such sponsored content is outside the
scope of procedures detailed below.
TNS LLC has not been compensated;
directly or indirectly; for producing or publishing this
document.
PRESS RELEASE
PROCEDURES
The non-sponsored content contained
herein has been prepared by a writer (the "Author") and is fact
checked and reviewed by a third-party research service company (the
"Reviewer") represented by a chartered financial analyst, for
further information on analyst credentials, please email
editor@tradersnewssource.com. TNS LLC provides necessary guidance
in preparing the document templates. The Reviewer has reviewed and
revised the content, as necessary, based on publicly available
information which is believed to be reliable. Content is
researched, written, and reviewed on a reasonable-effort basis. The
Reviewer has not performed any independent investigations or
forensic audits to validate the information herein. The Reviewer
has only independently reviewed the information provided by the
Author per the procedures outlined by TNS. TNS is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents, or
reports. Unless otherwise noted, any content outside of this
document has no association with the Author or the Reviewer in any
way.
NO
WARRANTY
TNS, the Author, and the Reviewer are
not responsible for any error which may be occasioned at the time
of printing of this document or any error, mistake, or shortcoming.
No liability is accepted whatsoever for any direct, indirect, or
consequential loss arising from the use of this document. TNS, the
Author, and the Reviewer expressly disclaim any fiduciary
responsibility or liability for any consequences, financial or
otherwise arising from any reliance placed on the information in
this document. Additionally, TNS, the Author, and the Reviewer do
not (1) guarantee the accuracy, timeliness, completeness, or
correct sequencing of the information, or (2) warrant any results
from use of the information. The included information is subject to
change without notice.
NOT AN
OFFERING
This document is not intended as an
offering, recommendation, or a solicitation of an offer to buy or
sell the securities mentioned or discussed and is to be used for
informational purposes only. Please read all associated disclosures
and disclaimers in full before investing. Neither TNS nor any party
affiliated with us is a registered investment adviser or
broker-dealer with any agency or in any jurisdiction whatsoever. To
download our report(s), read our disclosures, or for more
information, visit http://www.tradersnewssource.com.
For any questions, inquiries, or
comments reach out to us directly. If you're a company we are
covering and wish to no longer be featured on our coverage list,
contact us via email at: editor@tradersnewssource.com
CFA® and Chartered Financial Analyst®
are registered trademarks owned by CFA Institute.
CONTACT:
editor@tradersnewssource.com
SOURCE: Traders News
Source
Rising Biosciences (CE) (USOTC:RBII)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Rising Biosciences (CE) (USOTC:RBII)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024